Heart failure, systolic: Angiotensin II receptor blockers use
DISEASE INTERVENTION COMPARISON RESULTS
N Engl J Med. 2003 Nov 13;349(20):1893-906 Randomized Controlled Trial, Multicenter Study
IN coronary disease, myocardial infarction, heart failure, chronic, systolic The Use of
angiotensin II receptor blockers, valsartan, alone or combined with ACE inhibitors
As Treatment, Chronic
Is equal Than
angiotensin converting enzyme (ACE) inhibitors, captopril
To modify overall mortality (about 9.97% per year in valsartan, 9.75% per year in captopril and 9.63% per year with combined treatment) Combining valsartan + captopril did not increased survival but it did adverse events
Lancet. 2003 Sep 6;362(9386):767-71 Randomized Controlled Trial, Multicenter Study
IN heart failure, chronic, systolic The Use of
angiotensin II receptor blockers (candesartan), added to angiotensin converting enzyme inhibitors
As Treatment, Chronic
Is better Than
angiotensin converting enzyme (ACE) inhibitors alone
To reduce, at 3.5 years, cardiac events (cardiac death or hospital admission for heart failure): 38% with sartan added VS 42% with AECI alone
Lancet. 2003 Sep 6;362(9386):772-6 Randomized Controlled Trial, Multicenter Study
IN heart failure, chronic, systolic The Use of
angiotensin II receptor blockers (candesartan), as sustitute of non tolered angiotensin converting enzyme inhibitors
As Treatment, Chronic
Is better Than
placebo
To reducing combined outcome cardio-vascular death or hospital admission for heart failure (33% in intv. / 40% in cont. in 34 months)
Lancet. 2000 May 6;355(9215):1582-1587 Randomized Controlled Trial
IN heart failure, chronic, systolic The Use of
angiotensin II receptor blockers, losartan
As Treatment, Chronic
Is equal Than
angiotensin converting enzyme (ACE) inhibitors, captopril
To reduce, at about 2 years, all-cause mortality: 11.7% losartan VS 10.4% captopril. Losartan had less adverse effects: 9.7% discontinued Tt VS 14.7% with captopril, mainly becuase cought
Lancet. 1997 Mar 15;349(9054):747-52 Randomized Controlled Trial
IN heart failure, chronic, systolic The Use of
angiotensin II receptor blockers, losartan
As Treatment, Chronic
Is equal Than
angiotensin converting enzyme inhibitors (ACEI), captopril
To avoid worsening renal dysfunction, defined as a persistent increase in serum creatinine: 10.5% in each group. There was a significant difference in mortality, secondary end-point, not confirmed in the next trial ELITE-II.
Ann Intern Med. 2004 Nov 2;141(9):693-704 Meta-Analysis
IN heart failure, chronic, systolic, coronary disease, acute myocardial infarction The Use of
angiotensin II receptor blockers, added to or replacing angiotensin converting enzyme (ACE) inhibitors
As Treatment, Chronic
Is equal Than
angiotensin converting enzyme (ACE) inhibitors alone
To modify all-cause mortality or heart failure hospitalization.